Opportunities for metastatic triple negative breast cancer therapy

Metastatic triple negative breast cancer (mTNBC) is a difficult task for the chemotherapist in view of the disease aggressiveness, biological heterogeneity of the tumor, as well as the limit of therapy options. The approved modern drugs, such as immunotherapy and PARP inhibitors, have improved the t...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Inna P. Ganshina, Olga O. Gordeeva, Mariam S. Manukyan
Formato:	article
Lenguaje:	RU
Publicado:	IP Habib O.N. 2021
Materias:	triple negative breast cancer immunotherapy conjugated drugs akt inhibitors atezolizumab drug therapy Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/e5e8540deb5c4e00b4faf4caee137f8e
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:e5e8540deb5c4e00b4faf4caee137f8e
record_format	dspace
spelling	oai:doaj.org-article:e5e8540deb5c4e00b4faf4caee137f8e2021-11-30T16:55:00ZOpportunities for metastatic triple negative breast cancer therapy1815-14341815-144210.26442/18151434.2021.1.200761https://doaj.org/article/e5e8540deb5c4e00b4faf4caee137f8e2021-05-01T00:00:00Zhttps://modernonco.orscience.ru/1815-1434/article/viewFile/50011/pdfhttps://doaj.org/toc/1815-1434https://doaj.org/toc/1815-1442Metastatic triple negative breast cancer (mTNBC) is a difficult task for the chemotherapist in view of the disease aggressiveness, biological heterogeneity of the tumor, as well as the limit of therapy options. The approved modern drugs, such as immunotherapy and PARP inhibitors, have improved the treatment results in women with mTNBC. However, not all women are the candidates for this kind of therapy due to the lack of suitable points of application. In this context, high hopes are placed on the new treatment options currently being studied in clinical trials. The review summarizes data on advanced drugs that have demonstrated their efficacy in this multiplex group of women, but not yet registered at the territory of the Russian Federation Russian Federation, and will allow us to form an idea of the future algorithm of treatment of women with mTNBC.Inna P. GanshinaOlga O. GordeevaMariam S. ManukyanIP Habib O.N.articletriple negative breast cancerimmunotherapyconjugated drugsakt inhibitorsatezolizumabdrug therapyNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282RUСовременная онкология, Vol 23, Iss 1, Pp 78-81 (2021)
institution	DOAJ
collection	DOAJ
language	RU
topic	triple negative breast cancer immunotherapy conjugated drugs akt inhibitors atezolizumab drug therapy Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	triple negative breast cancer immunotherapy conjugated drugs akt inhibitors atezolizumab drug therapy Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Inna P. Ganshina Olga O. Gordeeva Mariam S. Manukyan Opportunities for metastatic triple negative breast cancer therapy
description	Metastatic triple negative breast cancer (mTNBC) is a difficult task for the chemotherapist in view of the disease aggressiveness, biological heterogeneity of the tumor, as well as the limit of therapy options. The approved modern drugs, such as immunotherapy and PARP inhibitors, have improved the treatment results in women with mTNBC. However, not all women are the candidates for this kind of therapy due to the lack of suitable points of application. In this context, high hopes are placed on the new treatment options currently being studied in clinical trials. The review summarizes data on advanced drugs that have demonstrated their efficacy in this multiplex group of women, but not yet registered at the territory of the Russian Federation Russian Federation, and will allow us to form an idea of the future algorithm of treatment of women with mTNBC.
format	article
author	Inna P. Ganshina Olga O. Gordeeva Mariam S. Manukyan
author_facet	Inna P. Ganshina Olga O. Gordeeva Mariam S. Manukyan
author_sort	Inna P. Ganshina
title	Opportunities for metastatic triple negative breast cancer therapy
title_short	Opportunities for metastatic triple negative breast cancer therapy
title_full	Opportunities for metastatic triple negative breast cancer therapy
title_fullStr	Opportunities for metastatic triple negative breast cancer therapy
title_full_unstemmed	Opportunities for metastatic triple negative breast cancer therapy
title_sort	opportunities for metastatic triple negative breast cancer therapy
publisher	IP Habib O.N.
publishDate	2021
url	https://doaj.org/article/e5e8540deb5c4e00b4faf4caee137f8e
work_keys_str_mv	AT innapganshina opportunitiesformetastatictriplenegativebreastcancertherapy AT olgaogordeeva opportunitiesformetastatictriplenegativebreastcancertherapy AT mariamsmanukyan opportunitiesformetastatictriplenegativebreastcancertherapy
_version_	1718406476754583552

Opportunities for metastatic triple negative breast cancer therapy

Ejemplares similares